[{"id":"45bb8668-6bf6-4a6d-88ea-82b1b4906deb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04074967","created_at":"2021-01-29T07:19:39.816Z","updated_at":"2025-02-25T17:30:00.515Z","phase":"Phase 1/2","brief_title":"Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab","source_id_and_acronym":"NCT04074967","lead_sponsor":"Jason J. Luke, MD","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • pexmetinib (ARRY-614)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 06/11/2020","start_date":" 06/11/2020","primary_txt":" Primary completion: 10/16/2024","primary_completion_date":" 10/16/2024","study_txt":" Completion: 10/16/2025","study_completion_date":" 10/16/2025","last_update_posted":"2025-01-30"}]